1. Research Framework
1.1. Research Objective
1.2. Product Overview
1.3. Market Segmentation
2. Executive Summary
3. North America Cancer Diagnostics Market Insights
3.1. Industry Value Chain Analysis
3.2. DROC Analysis
3.2.1. Growth Drivers
3.2.1.1. Rising cancer incidence
3.2.1.2. Aging population
3.2.1.3. Growing awareness about the importance of early cancer detection
3.2.1.4. Increasing government initiatives
3.2.2. Restraints
3.2.2.1. High cost of diagnostics
3.2.2.2. Data privacy concerns
3.2.2.3. Shortage of skilled professionals
3.2.3. Opportunities
3.2.3.1. Increasing development in the healthcare infrastructure
3.2.3.2. Growing focus on personalized medicine
3.2.4. Challenges
3.2.4.1. Increasing cybersecurity threats
3.2.4.2. Addressing public concerns and misinformation about new technologies
3.3. Technological Advancements/Recent Developments
3.4. Regulatory Framework
3.5. Porter's Five Forces Analysis
3.5.1. Bargaining Power of Suppliers
3.5.2. Bargaining Power of Buyers
3.5.3. Threat of New Entrants
3.5.4. Threat of Substitutes
3.5.5. Intensity of Rivalry
4. North America Cancer Diagnostics Market: Marketing Strategies
5. North America Cancer Diagnostics Market Overview
5.1. Market Size & Forecast, 2019-2030
5.1.1. By Value (USD Million)
5.2. Market Share and Forecast
5.2.1. By Products
5.2.1.1. Instruments
5.2.1.1.1. Pathology-based Instruments
5.2.1.1.2. Imaging Instruments
5.2.1.1.3. Others
5.2.1.2. Consumables
5.2.1.2.1. Antibodies
5.2.1.2.2. Kits & Reagents
5.2.1.2.3. Probes
5.2.1.2.4. Others
5.2.1.3. Services
5.2.2. By Test Type
5.2.2.1. Imaging Tests
5.2.2.2. Biopsy and Cytology Tests
5.2.2.3. Tumor Biomarkers
5.2.2.4. Immunohistochemistry
5.2.2.5. In Situ Hybridization
5.2.2.6. Others (Endoscopy, Genetic Tests)
5.2.3. By Application
5.2.3.1. Breast Cancer
5.2.3.2. Cervical Cancer
5.2.3.3. Lung Cancer
5.2.3.4. Blood Cancer
5.2.3.5. Kidney Cancer
5.2.3.6. Pancreatic Cancer
5.2.3.7. Ovarian Cancer
5.2.3.8. Liver Cancer
5.2.3.9. Others (Including Skin Cancer, Colorectal Cancer, Prostate Cancer etc.)
5.2.4. By End User
5.2.4.1. Hospitals
5.2.4.2. Cancer Research Institutes
5.2.4.3. Diagnostic Laboratories
5.2.4.4. Others
5.2.5. By Country
5.2.5.1. United States
5.2.5.2. Canada
6. United States Cancer Diagnostics Market
6.1. Market Size & Forecast, 2019-2030
6.1.1. By Value (USD Million)
6.2. Market Share & Forecast
6.2.1. By Products
6.2.2. By Test Type
6.2.3. By Application
6.2.4. By End User
7. Canada Cancer Diagnostics Market
7.1. Market Size & Forecast, 2019-2030
7.1.1. By Value (USD Million)
7.2. Market Share & Forecast
7.2.1. By Products
7.2.2. By Test Type
7.2.3. By Application
7.2.4. By End User
8. Competitive Landscape
8.1. List of Key Players and Their Offerings
8.2. North America Cancer Diagnostics Market Share Analysis, 2023
8.3. Competitive Benchmarking, By Operating Parameters
8.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)
9. Impact of Geopolitical Tension on North America Cancer Diagnostics Market
10. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)
10.1. Roche Diagnostics
10.2. Cancer Diagnostics, Inc.
10.3. Agilent Technologies
10.4. BD
10.5. Telix Pharmaceuticals Limited
10.6. Abbott
10.7. NeoGenomics Laboratories, Inc
10.8. Telerad Tech
10.9. The Menarini Group
10.10. Hologic, Inc
10.11. Illumina, Inc.
10.12. Thermo Fisher Scientific Inc.,
10.13. QIAGEN
10.14. Epredia
10.15. Other Prominent Players
11. Key Strategic Recommendations
12. Research Methodology
12.1. Qualitative Research
12.1.1. Primary & Secondary Research
12.2. Quantitative Research
12.3. Market Breakdown & Data Triangulation
12.3.1. Secondary Research
12.3.2. Primary Research
12.4. Breakdown of Primary Research Respondents, By Country
12.5. Assumptions & Limitations
*Financial information of case of non-listed companies can be provided as per availability.
**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable